Publications

  1. Ding Y, Holmes JM, Feng H, Li B, McGee LA, Rwigema JM, Vora SA, Wong WW, Ma DJ, Foote RL, Patel SH, Liu W. Accurate patient alignment without unnecessary imaging using patient-specific 3D CT images synthesized from 2D kV images. Commun Med (Lond). 2024 Nov 21; 4 (1):241
    View PubMed
  2. Vora S, Pafundi D, Voss M, Buras M, Ashman J, Bendok B, Breen W, Hu L, Kizilbash S, Laack N, Liu W, Mahajan A, Mrugala M, Porter A, Ruff M, Sio T, Uhm J, Yang M, Brinkmann D, Brown P. Short-course hypofractionated proton beam therapy, incorporating (18)F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial. Lancet Oncol. 2024 Nov 18 [Epub ahead of print]
    View PubMed
  3. Chen J, Yang Y, Feng H, Zhang L, Liu Z, Liu T, Vargas CE, Yu NY, Rwigema JM, Keole SR, Patel SH, Vora SA, Shen J, Liu W. Robust Optimization for Spot Scanning Proton Therapy based on Dose-Linear Energy Transfer (LET) Volume Constraints. Int J Radiat Oncol Biol Phys. 2024 Nov 15 [Epub ahead of print]
    View PubMed
  4. Holmes J, Zhang L, Ding Y, Feng H, Liu Z, Liu T, Wong WW, Vora SA, Ashman JB, Liu W. Benchmarking a Foundation Large Language Model on its Ability to Relabel Structure Names in Accordance With the American Association of Physicists in Medicine Task Group-263 Report. Pract Radiat Oncol. 2024 Nov-Dec; 14 (6):e515-e521 Epub 2024 Sept 05
    View PubMed
  5. Vora SA, Pafundi DH, DeWees TA, Voss MM, Ashman JB, Bendok BR, Laack NN, Liu W, Mahajan A, Mrugala MM, Porter AB, Sio TT, Uhm JH, Yang M, Brinkmann DH, Brown PD. Short-Course, Hypofractionated Proton Beam Therapy Incorporating 18F-DOPA PET–MRI for Older Patients With Newly Diagnosed Glioblastoma: A Prospective Phase 2 Trial The Lancet Oncology (Manuscript accepted pending revisions-24-00665R2). 2024.
  6. Gunn HJ, Zaniletti I, Breen WG, Leavitt T, Bogan A, Mahajan A, Brown PD, Yan E, Vora SA, Merrell KW, Ashman JB, Peterson JL, Leenstra JL, Wilson ZC, Laughlin BS, Laack NN, DeWees TA. Establishing the minimal clinically important difference of the Brief Fatigue Inventory for brain or CNS cancer patients undergoing radiotherapy. Neurooncol Pract. 2024 Oct; 11 (5):633-639 Epub 2024 Apr 27
    View PubMed
  7. Feng H, Shan J, Vargas CE, Keole SR, Rwigema JM, Yu NY, Ding Y, Zhang L, Hu Y, Schild SE, Wong WW, Vora SA, Shen J, Liu W. Online Adaptive Proton Therapy Facilitated by Artificial Intelligence-Based Autosegmentation in Pencil Beam Scanning Proton Therapy. Int J Radiat Oncol Biol Phys. 2024 Sep 20 Epub 2024 Sept 20
    View PubMed
  8. Sujay , Deanna, Molly , Matthew, Jonathan, Bernard, William, Leland Hu, Sani, Nadia, Wei, Anita, Maciej, Alyx, Michael, Terence, Joon, Ming, Debra, Paul. Phase 2 Study of Short-Course, Hypofractionated Proton Beam Therapy Incorporating 18F-DOPA PET–MRI for Older Patients With Newly Diagnosed Glioblastoma (In review with Editor, Manuscript Number: D-24-00665R1) The Lancet Oncology. 2024.
  9. Vora SA, Pafundi DH, Voss MM, Buras MR, Ashman JB, Bendok BR, Breen W, Hu LS, Kizilbash SH, Laack NN, Liu W, Mahajan A, Mrugala MM, Porter Umphrey AB, Ruff MW, Sio TT, Uhm J, Yang M, Brinkmann DH, Brown PD. Phase 2 Study of Short-Course, Hypofractionated Proton Beam Therapy Incorporating 18F-DOPA PET–MRI for Older Patients With Newly Diagnosed Glioblastoma (In review with Editor, Manuscript Number: D-24-00665R1) The Lancet. 2024.
  10. Routman DM, Jusue-Torres I, Brown PD, Trifiletti DM, Vora SA, Brown DA, Parney IF, Burns TC, Yan E. Pre-operative vs. post-operative stereotactic radiosurgery for operative metastatic brain tumors: study protocol for a phase III clinical trial. BMC Cancer. 2024 Mar 12; 24 (1):332
    View PubMed
  11. Zhang L, Liu Z, Zhang L, Wu Z, Yu X, Holmes J, Feng H, Dai H, Li X, Li Q, Wong WW, Vora SA, Zhu D, Liu T, Liu W. Technical note: Generalizable and promptable artificial intelligence model to augment clinical delineation: segment anything model (SAM) in radiation oncology. Med Phys. 2024 Mar; 51 (3):2187-2199 Epub 2024 Feb 06
    View PubMed
  12. Zhang L, Holmes JM, Liu Z, Vora SA, Sio TT, Vargas CE, Yu NY, Keole SR, Schild SE, Bues M, Li S, Liu T, Shen J, Wong WW, Liu W. Beam mask and sliding window-facilitated deep learning-based accurate and efficient dose prediction for pencil beam scanning proton therapy. Med Phys. 2024 Feb; 51 (2):1484-1498 Epub 2023 Sept 25
    View PubMed
  13. Feng H, Holmes JM, Vora SA, Stoker JB, Bues M, Wong WW, Sio T, Foote RL, Patel SH, Shen J, Liu W. Modelling small block aperture in an in-house developed GPU-accelerated Monte Carlo-based dose engine for pencil beam scanning proton therapy. Phys Med Biol. 2024 Jan 17; 69 (3)
    View PubMed
  14. Hu J, Fatyga M, Liu W, Schild SE, Wong WW, Vora SA, Li J. Radiotherapy toxicity prediction using knowledge-constrained generalized linear model. IISE Trans Healthc Syst Eng. 2024; 14 (2):130-140 Epub 2023 July 07
    View PubMed
  15. Anderson JD, Voss MM, Laughlin BS, Garda AE, Aziz K, Mullikin TC, Haddock MG, Petersen IA, DeWees TA, Vora SA. Outcomes of Proton Beam Therapy Compared With Intensity-Modulated Radiation Therapy for Uterine Cancer. Int J Part Ther. 2023 Winter; 9 (3):10-17 Epub 2022 Nov 14
    View PubMed
  16. Ding Y, Holmes J, Li B, Vargas CE, Vora SA, Wong WW, Fatyga M, Foote RL, Patel SH, Liu W. Patient-Specific 3D CT Images Reconstruction from 2D KV Images Via Vision Transformer-Based Deep-Learning. Int J Radiat Oncol Biol Phys. 2023 Oct 1; 117 (2S):e660
    View PubMed
  17. Shen J, Robertson DG, Bues M, Shipulin K, Liu W, Stoker J, Ashman JB, Lara P, Keole SR, Wong W, Vora SA. Technical note: Comprehensive evaluations of gantry and couch rotation isocentricities for implementing proton stereotactic radiosurgery. Med Phys. 2023 Jun; 50 (6):3359-3367 Epub 2023 Apr 06
    View PubMed
  18. Chhabra AM, Rice SR, Holtzman A, Choi JI, Hasan S, Press RH, Chang J, Halasz L, Tsai HK, Wang CJ, Kabolizadeh P, Gondi V, Hartsell WF, Vora SA, Vargas CE, Simone CB 2nd. Clinical outcomes and toxicities of 100 patients treated with proton therapy for chordoma on the proton collaborative group prospective registry. Radiother Oncol. 2023 Jun; 183:109551 Epub 2023 Feb 20
    View PubMed
  19. Choo R, Hillman DW, Mitchell C, Daniels T, Vargas C, Rwigema JC, Corbin K, Keole S, Vora S, Merrell K, Stish B, Pisansky T, Davis BJ, Amundson A, Wong W. Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023 Apr 1; 115 (5):1085-1094 Epub 2022 Nov 22
    View PubMed
  20. Thomson HM, Fortin Ensign SP, Edmonds VS, Sharma A, Butterfield RJ 3rd, Schild SE, Ashman JB, Zimmerman RS, Patel NP, Bryce AH, Vora SA, Sio TT, Porter AB. Clinical Outcomes of Stereotactic Radiosurgery-Related Radiation Necrosis in Patients with Intracranial Metastasis from Melanoma. Clin Med Insights Oncol. 2023; 17:11795549231161878. Epub 2023 Mar 21.
    View PubMed
  21. De La Pena NM, Singh R, Anderson ML, Koester SW, Sio TT, Ashman JB, Vora SA, Patel NP. High-Dose Frameless Stereotactic Radiosurgery for Trigeminal Neuralgia: A Single-Institution Experience and Systematic Review. World Neurosurg. 2022 Nov; 167:e432-e443 Epub 2022 Aug 13
    View PubMed
  22. Yang Y, Patel SH, Bridhikitti J, Wong WW, Halyard MY, McGee LA, Rwigema JM, Schild SE, Vora SA, Liu T, Bues M, Fatyga M, Foote RL, Liu W. Exploratory study of seed spots analysis to characterize dose and linear-energy-transfer effect in adverse event initialization of pencil-beam-scanning proton therapy. Med Phys. 2022 Sep; 49 (9):6237-6252 Epub 2022 July 21
    View PubMed
  23. Moassefi M, Faghani S, Conte GM, Kowalchuk RO, Vahdati S, Crompton DJ, Perez-Vega C, Cabreja RAD, Vora SA, Quiñones-Hinojosa A, Parney IF, Trifiletti DM, Erickson BJ. A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients. J Neurooncol. 2022 Sep; 159(2):447-455. Epub 2022 Jul 19.
    View PubMed
  24. Halasz LM, Attia A, Bradfield L, Brat DJ, Kirkpatrick JP, Laack NN, Lalani N, Lebow ES, Liu AK, Niemeier HM, Palmer JD, Peters KB, Sheehan J, Thomas RP, Vora SA, Wahl DR, Weiss SE, Yeboa DN, Zhong J, Shih HA. Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2022 Sep-Oct; 12 (5):370-386 Epub 2022 May 31
    View PubMed
  25. Laughlin BS, Anderson JD, Gagneur JD, Chungbin SJ, Bues M, Hobbis D, Fatyga M, Korte SM, Carroll SE, Vora S, Sio TT, Wong WW, Keole SR, Rong Y. Implementation of Photon Treatment Back-up Workflow at a High-Volume Proton Center: Safety, Quality, and Patient Considerations. Pract Radiat Oncol. 2022 Sep-Oct; 12 (5):e453-e459 Epub 2022 Mar 07
    View PubMed
  26. Kong MJ, Yang AF, Vora SA, Ross JS, Yang M. The Complementary Role of (68)Ga-DOTATATE PET/CT in Diagnosis of Recurrent Meningioma. J Nucl Med Technol. 2022 Aug 30 [Epub ahead of print]
    View PubMed
  27. Ramos-Fresnedo A, Domingo RA, Sanchez-Garavito JE, Perez-Vega C, Akinduro OO, Jentoft ME, Vora SA, Brown PD, Porter AB, Bendok BR, Link MJ, Middlebrooks EH, Trifiletti DM, Chaichana KL, Quinones-Hinojosa A, Sherman WJ. The impact of multiple lesions on progression-free survival of meningiomas: a 10-year multicenter experience. J Neurosurg. 2022 Jul 1; 137 (1):9-17 Epub 2021 Nov 19
    View PubMed
  28. Penoncello GP, Gagneur JD, Vora SA, Yu NY, Fatyga M, Mrugala MM, Bendok BR, Rong Y. Comprehensive Commissioning and Clinical Implementation of GammaTiles STaRT for Intracranial Brain Cancer. Adv Radiat Oncol. 2022 Jul-Aug; 7 (4):100910 Epub 2022 Feb 05
    View PubMed
  29. Akinduro OO, De Biase G, Goyal A, Meyer JH, Sandhu SJS, Kowalchuk RO, Trifiletti DM, Sheehan J, Merrell KW, Vora SA, Broderick DF, Clarke MJ, Bydon M, McClendon J Jr, Kalani MA, Quiñones-Hinojosa A, Abode-Iyamah K. Focused versus conventional radiotherapy in spinal oncology: is there any difference in fusion rates and pseudoarthrosis? J Neurooncol. 2022 Jan; 156(2):329-339. Epub 2022 Jan 07.
    View PubMed
  30. Laughlin BS, Silva AC, Vora SA, Keole SR, Wong WW, Schild MH, Schild SE. Long-term outcomes of prostate intensity-modulated radiation therapy incorporating a simultaneous intra-prostatic MRI-directed boost. Front Oncol. 2022; 12:921465 Epub 2022 Aug 10
    View PubMed
  31. Delara R, Yang J, Suarez-Salvador E, Vora S, Magrina J, Butler K, Magtibay P. Radical Extirpation With Intraoperative Radiotherapy for Locally Recurrent Gynecologic Cancer: An Institutional Review. Mayo Clin Proc Innov Qual Outcomes. 2021 Dec; 5 (6):1081-1088 Epub 2021 Nov 19
    View PubMed
  32. Choo R, Hillman DW, Daniels T, Vargas C, Rwigema JC, Corbin K, Keole S, Vora S, Merrell K, Stish B, Pisansky T, Davis B, Amundson A, Wong W. Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity. Int J Part Ther. 2021 Fall; 8 (2):41-50 Epub 2021 Sept 14
    View PubMed
  33. Neal MT, Richards AE, Curley KL, Patel NP, Ashman JB, Vora SA, Kalani MA. Carbon fiber-reinforced PEEK instrumentation in the spinal oncology population: a retrospective series demonstrating technique, feasibility, and clinical outcomes. Neurosurg Focus. 2021 May; 50 (5):E13
    View PubMed
  34. Yang J, Delara R, Magrina J, Magtibay P, Langstraat C, Dinh T, Karlin N, Vora SA, Butler K. Management and outcomes of primary vaginal Cancer. Gynecol Oncol. 2020 Nov; 159 (2):456-463 Epub 2020 Sept 22
    View PubMed
  35. Yu NY, Sio TT, Lyons MK, Vora SA, Turkmani A, Brown PD, Park SS, Leenstra JL, Bendok BR, Schild SE, Ashman JB. Linear accelerator-based single-fraction stereotactic body radiotherapy for symptomatic vertebral body hemangiomas: The Mayo Clinic experience. J Clin Neurosci. 2020 Oct; 80:74-78 Epub 2020 Aug 17
    View PubMed
  36. Bhangoo RS, DeWees TA, Yu NY, Ding JX, Liu C, Golafshar MA, Rule WG, Vora SA, Ross HJ, Ahn DH, Beamer SE, Jaroszewski DE, Hallemeier CL, Liu W, Ashman JB, Sio TT. Acute Toxicities and Short-Term Patient Outcomes After Intensity-Modulated Proton Beam Radiation Therapy or Intensity-Modulated Photon Radiation Therapy for Esophageal Carcinoma: A Mayo Clinic Experience. Adv Radiat Oncol. 2020 Sep-Oct; 5 (5):871-879 Epub 2020 May 19
    View PubMed
  37. Patra DP, Hess RA, Turcotte EL, Welz ME, Rahme RJ, Maiti TK, Abi-Aad KR, AlMekkawi AK, Keole S, Lal D, Marino M, Mrugala M, Porter A, Vora S, Bendok BR. Surgical Outcomes with Midline versus Lateral Approaches for Cranial Base Chordomas: A Systematic Review and Meta-Analysis. World Neurosurg. 2020 Aug; 140:378-388.e2 Epub 2020 Apr 14
    View PubMed
  38. Whitmire P, Rickertsen CR, Hawkins-Daarud A, Carrasco E Jr, Lorence J, De Leon G, Curtin L, Bayless S, Clark-Swanson K, Peeri NC, Corpuz C, Lewis-de Los Angeles CP, Bendok BR, Gonzalez-Cuyar L, Vora S, Mrugala MM, Hu LS, Wang L, Porter A, Kumthekar P, Johnston SK, Egan KM, Gatenby R, Canoll P, Rubin JB, Swanson KR. Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients. BMC Cancer. 2020 May 19; 20 (1):447
    View PubMed
  39. Sharma A, Mountjoy LJ, Butterfield RJ, Zhang N, Ross HJ, Schild SE, Sio TT, Daniels TB, Paripati HR, Mrugala MM, Vora SA, Patel NP, Zimmerman RS, Ashman JB, Porter AB. Expanding the Spectrum of Radiation Necrosis After Stereotactic Radiosurgery (SRS) for Intracranial Metastases From Lung Cancer: A Retrospective Review. Am J Clin Oncol. 2020 Feb; 43 (2):128-132
    View PubMed
  40. Massey SC, White H, Whitmire P, Doyle T, Johnston SK, Singleton KW, Jackson PR, Hawkins-Daarud A, Bendok BR, Porter AB, Vora S, Sarkaria JN, Hu LS, Mrugala MM, Swanson KR. Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma. PLoS One. 2020; 15 (3):e0230492 Epub 2020 Mar 27
    View PubMed
  41. Valencia-Sanchez C, Gorelkin VC, Mrugala MM, Sharma A, Vora SA, Ashman JB, Daniels TB, Halyard MY, Rule WG, Zhang N, Butterfield RJ, Schild SE, Porter AB. Clinical evaluation of fitness to drive in patients with brain metastases. Neurooncol Pract. 2019 Dec; 6 (6):484-489 Epub 2019 July 03
    View PubMed
  42. Yu N, Vora SA. Case Report with Literature Review: Retroperitoneal Chordoma treated with Proton Beam Therapy. Rare Cancers (accepted). 2019.
  43. Fega KR, Fletcher GP, Waddle MR, Peterson JL, Ashman JB, Barrs DM, Bendok BR, Patel NP, Porter AB, Vora SA. Analysis of MRI Volumetric Changes After Hypofractionated Stereotactic Radiation Therapy for Benign Intracranial Neoplasms. Adv Radiat Oncol. 2019 Jan-Mar; 4 (1):43-49 Epub 2018 Aug 23
    View PubMed
  44. Stoker JB, Grosshans D, Patel A, Allred B, Uejo A, Daniels TB, Vern-Gross TZ, Vora SA, Bues M. Hippocampal Sparing Intensity-Modulated Proton Therapy. (Manuscript accepted). 2019.
  45. Yu NY, Vora SA. Dosimetric advantages of proton beam therapy compared to intensity-modulated radiation therapy for retroperitoneal chordoma. Rare Tumors. 2019; 11:2036361319878518 Epub 2019 Sept 23
    View PubMed
  46. Rayfield CA, Grady F, De Leon G, Rockne R, Carrasco E, Jackson P, Vora M, Johnston SK, Hawkins-Daarud A, Clark-Swanson KR, Whitmire S, Gamez ME, Porter A, Hu L, Gonzalez-Cuyar L, Bendok B, Vora S, Swanson KR. Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival. JCO Clin Cancer Inform. 2018 Dec; 2:1-14.
    View PubMed
  47. Tseng YD, Hartsell W, Tsai H, Badiyan S, Wang CJ, Rossi C, Kotecha R, Vora S, Vargas C, Larson G, Halasz LM. Proton therapy patterns of care among pediatric and adult patients with CNS tumors. Neuro Oncol. 2018 Oct 9; 20 (11):1556-1557
    View PubMed
  48. Stoker J, Vora S, Patel A, Grosshans D, Brown PD, Vern-Gross T, Bues M, Daniels T, Allred B, Uejo A, Kosiorek H, Bruso M, Keole S. Advantages of intensity modulated proton therapy during hippocampal avoidance whole brain radiation therapy. Phys Imaging Radiat Oncol. 2018 Oct; 8:28-32 Epub 2018 Nov 27
    View PubMed
  49. Hobbs CJ, Ko SJ, Paryani NN, Accurso JM, Olivier KR, Garces YI, Park SS, Hallemeier CL, Schild SE, Vora SA, Ashman JB, Rule WG, Bowers JR, Heckman MG, Diehl NN, Miller RC. Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non-Small Cell Lung Cancer: The Mayo Clinic Experience. Mayo Clin Proc Innov Qual Outcomes. 2018 Mar; 2 (1):40-48 Epub 2017 Dec 26
    View PubMed
  50. Liu X, Li J, Schild SE, Li J, Schild MH, Wong W, Vora S, Herman MG, Fatyga M. Modeling of Acute Rectal Toxicity to Compare Two Patient Positioning Methods for Prostate Cancer Radiotherapy: Can Toxicity Modeling be Used for Quality Assurance? OMICS J Radiol. 2018; 7 (5) Epub 2018 Dec 03
    View PubMed
  51. Routman DM, Yan E, Vora S, Peterson J, Mahajan A, Chaichana KL, Laack N, Brown PD, Parney IF, Burns TC, Trifiletti DM. Preoperative Stereotactic Radiosurgery for Brain Metastases. Front Neurol. 2018; 9:959 Epub 2018 Nov 13
    View PubMed
  52. Wong WW, Anderson EM, Mohammadi H, Daniels TB, Schild SE, Keole SR, Choo CR, Tzou KS, Bryce AH, Ho TH, Quevedo FJ, Vora SA. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Dec; 15(6):e969-e975. Epub 2017 Apr 26.
    View PubMed
  53. Schild MH, Schild SE, Wong WW, Vora SA, Keole SR, Vargas CE, Daniels TB, Ezzell GA, Nguyen BD, Roarke MC. A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT. Int J Radiat Oncol Biol Phys. 2017 Apr 1; 97 (5):1021-1025 Epub 2017 Feb 01
    View PubMed
  54. Liu X, Li J, Schild SE, Schild MH, Wong W, Vora S, Herman MG, Fatyga M. Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther. 2017 Feb; 8 (2):73-85 Epub 2017 Feb 06
    View PubMed
  55. Liu X, Li J, Wu T, Schild SE, Schild MH, Wong W, Vora S, Fatyga M. Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade >/= 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol. 2016 Jun; 5 (3) Epub 2016 June 13
    View PubMed
  56. Rule WG, Foster NR, Meyers JP, Ashman JB, Vora SA, Kozelsky TF, Garces YI, Urbanic JJ, Salama JK, Schild SE. Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol. 2015 Mar; 6 (2):119-26 Epub 2014 Dec 04
    View PubMed
  57. Liu W, Liao Z, Schild SE, Liu Z, Li H, Li Y, Park PC, Li X, Stoker J, Shen J, Keole S, Anand A, Fatyga M, Dong L, Sahoo N, Vora S, Wong W, Zhu XR, Bues M, Mohan R. Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers. Pract Radiat Oncol. 2015 Mar-Apr; 5 (2):e77-86 Epub 2014 Sept 11
    View PubMed
  58. Schild MH, Schild SE, Wong WW, Vora SA, Silva AC, Silva AM, Daniels TB, Keole SR. Early Outcome of Prostate Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Intra-Prostatic MRI Directed Boost. OMICS J Radiol. 2014 Dec; 3 (4)
    View PubMed
  59. Schild SE, Rule WG, Ashman JB, Vora SA, Keole S, Anand A, Liu W, Bues M. Proton beam therapy for locally advanced lung cancer: A review. World J Clin Oncol. 2014 Oct 10; 5 (4):568-75
    View PubMed
  60. Wong WW, Pockaj BA, Vora SA, Halyard MY, Gray RJ, Schild SE. Six-year outcome of a prospective study evaluating tumor bed boost with intra-operative electron irradiation followed by whole-breast irradiation for early-stage breast cancer. Breast J. 2014 Mar-Apr; 20(2):125-30. Epub 2013 Dec 26.
    View PubMed
  61. Wisenbaugh ES, Andrews PE, Ferrigni RG, Schild SE, Keole SR, Wong WW, Vora SA. Proton beam therapy for localized prostate cancer 101: basics, controversies, and facts. Rev Urol. 2014; 16 (2):67-75
    View PubMed
  62. Vora SA, Wong WW, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. J Urol. 2013 Aug; 190 (2):521-6 Epub 2013 Feb 13
    View PubMed
  63. Paripati HR, Karlin NJ, Schild SE, Vora SA, Dueck AC, Ross HJ. Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer-A retrospective analysis. Journal of Geriatric Oncology. 2012; 3(2):104-10.
  64. Wong WW, Schild SE, Vora SA, Ezzell GA, Nguyen BD, Ram PC, Roarke MC. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81 (4):e423-9 Epub 2011 Apr 07
    View PubMed
  65. Wong WW, Vora SA, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer. 2009 Dec 1; 115 (23):5596-606
    View PubMed
  66. Nguyen BD, Schild SE, Wong WW, Vora SA. Prostate brachytherapy seed embolization to the right renal artery. Brachytherapy. 2009 Jul-Sep; 8: (3)309-12.
    View PubMed
  67. Schild MH, Wong WW, Vora SA, Ward LD, Nguyen BD. Embolization of an iodine-125 radioactive seed from the prostate gland into the right ventricle: An unusual pattern of seed migration. Radiography. 2009; 15(2):179-81.
  68. Lyons MK, Vora SA. Brain tumors: current issues in diagnosis and management. Semin Neurol. 2007 Sep; 27(4):312-24.
    View PubMed
  69. Vora SA, Wong WW, Schild SE, Ezzell GA, Halyard MY. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68 (4):1053-8 Epub 2007 Mar 29
    View PubMed
  70. Halyard MY, Jatoi A, Sloan JA, Bearden JD 3rd, Vora SA, Atherton PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, Stella PJ, Loprinzi CL. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys. 2007 Apr 1; 67 (5):1318-22
    View PubMed
  71. Schild SE, Wong WW, Vora SA, Halyard MY, Northfelt DW, Kogut HL, Wheeler RH. The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005 Aug 1; 62(5):1432-7.
    View PubMed
  72. Schwartz DJ, Schild SE, Wong WW, Vora SA. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005 Jan 1; 61(1):60-3.
    View PubMed
  73. MacDonald OK, Schild SE, Vora S, Andrews PE, Ferrigni RG, Novicki DE, Swanson SK, Wong WW. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ? Urology. 2004 Oct; 64(4):760-4.
    View PubMed
  74. Wong WW, Schild SE, Vora SA, Halyard MY. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Sep 1; 60(1):24-9.
    View PubMed
  75. Schild SE, Korte SM, Wong WW, Vora SA, Younggren JA, Ezzell GA. Treatment planning for dose escalation in non-small cell lung cancer (NSCLC). Med Dosim. 2004 Fall; 29(3):196-203.
    View PubMed
  76. Halyard MY, McCombs KE, Wong WW, Buchel EW, Pockaj BA, Vora SA, Gray RJ, Schild SE. Acute and chronic results of adjuvant radiotherapy after mastectomy and Transverse Rectus Abdominis Myocutaneous (TRAM) flap reconstruction for breast cancer. Am J Clin Oncol. 2004 Aug; 27 (4):389-94
    View PubMed
  77. Macdonald OK, Schild SE, Vora SA, Andrews PE, Ferrigni RG, Novicki DE, Swanson SK, Wong WW. Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2004 Apr 1; 58(5):1530-5.
    View PubMed
  78. Vora SA, Garner SL. Role of radiation therapy for facial skin cancers. Clin Plast Surg. 2004 Jan; 31 (1):33-8
    View PubMed
  79. Macdonald OK, Schild SE, Vora SA, Andrews PE, Ferrigni RG, Novicki DE, Swanson SK, Wong WW. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol. 2003 Nov; 170(5):1833-7.
    View PubMed
  80. Schild SE, Wong WW, Vora SA, Halyard MY, Wheeler RH. Phase I study of hyperfractionated accelerated radiotherapy and escalating doses of daily cisplatin for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002 Nov 1; 54 (3):729-34
    View PubMed
  81. Serago CF, Chungbin SJ, Buskirk SJ, Ezzell GA, Collie AC, Vora SA. Initial experience with ultrasound localization for positioning prostate cancer patients for external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2002 Aug 1; 53 (5):1130-8
    View PubMed
  82. Safran H, Moore T, Iannitti D, Dipetrillo T, Akerman P, Cioffi W, Harrington D, Quirk D, Rathore R, Cruff D, Vakharia J, Vora SA, Savarese D, Wanebo H. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. International Journal Radiation Oncology Biol Physics. 2001; 49(5):1275-9.
  83. Vora SA, Daly BD, Blaszkowsky L, McGrath JJ, Bankoff M, Supran S, Dipetrillo TA. High dose radiation therapy and chemotherapy as induction treatment for stage III nonsmall cell lung carcinoma. Cancer. 2000 Nov 1; 89(9):1946-52.
    View PubMed
  84. Vora SA, Wazer DE, Homer MJ. Management of microcalcifications that develop at the lumpectomy site after breast-conserving therapy. Radiology. 1997 Jun; 203(3):667-71.
    View PubMed
  85. Mangan DF, Novak MJ, Vora SA, Mourad J, Kriger PS. Lectinlike interactions of Fusobacterium nucleatum with human neutrophils. Infection & Immunity. 1989 Nov; 57(11):3601-11.
    View PubMed